Affimed (AFMD) Competitors $2.75 +0.03 (+1.10%) (As of 10:31 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AFMD vs. CRBU, DMAC, KYTX, INZY, ACTU, NKTX, TNYA, SCPH, ADAP, and HRTXShould you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Caribou Biosciences (CRBU), DiaMedica Therapeutics (DMAC), Kyverna Therapeutics (KYTX), Inozyme Pharma (INZY), Actuate Therapeutics (ACTU), Nkarta (NKTX), Tenaya Therapeutics (TNYA), scPharmaceuticals (SCPH), Adaptimmune Therapeutics (ADAP), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. Affimed vs. Caribou Biosciences DiaMedica Therapeutics Kyverna Therapeutics Inozyme Pharma Actuate Therapeutics Nkarta Tenaya Therapeutics scPharmaceuticals Adaptimmune Therapeutics Heron Therapeutics Affimed (NASDAQ:AFMD) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Do analysts recommend AFMD or CRBU? Affimed currently has a consensus price target of $16.00, indicating a potential upside of 481.82%. Caribou Biosciences has a consensus price target of $11.25, indicating a potential upside of 481.40%. Given Affimed's higher probable upside, equities research analysts plainly believe Affimed is more favorable than Caribou Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer AFMD or CRBU? In the previous week, Affimed had 9 more articles in the media than Caribou Biosciences. MarketBeat recorded 15 mentions for Affimed and 6 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.45 beat Affimed's score of 0.42 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Affimed 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, AFMD or CRBU? Caribou Biosciences has higher revenue and earnings than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAffimed$8.95M4.95-$114.66MN/AN/ACaribou Biosciences$34.48M5.08-$102.07M-$1.65-1.17 Is AFMD or CRBU more profitable? Caribou Biosciences has a net margin of -1,290.81% compared to Affimed's net margin of -7,836.26%. Caribou Biosciences' return on equity of -45.46% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Affimed-7,836.26% -193.84% -107.24% Caribou Biosciences -1,290.81%-45.46%-38.07% Do institutionals & insiders have more ownership in AFMD or CRBU? 30.8% of Affimed shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 3.8% of Affimed shares are owned by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, AFMD or CRBU? Affimed has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Does the MarketBeat Community favor AFMD or CRBU? Affimed received 414 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 70.14% of users gave Affimed an outperform vote while only 58.97% of users gave Caribou Biosciences an outperform vote. CompanyUnderperformOutperformAffimedOutperform Votes43770.14% Underperform Votes18629.86% Caribou BiosciencesOutperform Votes2358.97% Underperform Votes1641.03% SummaryCaribou Biosciences beats Affimed on 11 of the 16 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AFMD vs. The Competition Export to ExcelMetricAffimedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.28M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E RatioN/A4.9789.5613.60Price / Sales4.95371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book2.3510.306.976.33Net Income-$114.66M$153.61M$119.04M$225.93M7 Day Performance-24.66%-1.73%-1.78%-0.96%1 Month Performance-19.12%-7.26%-3.59%1.06%1 Year Performance-43.53%31.10%31.64%26.59% Affimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AFMDAffimed3.2493 of 5 stars$2.75+1.1%$16.00+481.8%-42.7%$44.28M$8.95M0.0076Analyst ForecastGap UpCRBUCaribou Biosciences2.9415 of 5 stars$1.94-1.3%$11.25+481.4%-64.7%$175.21M$34.48M0.00100DMACDiaMedica Therapeutics1.902 of 5 stars$4.07+1.2%$7.00+72.0%+62.8%$174.03MN/A0.0020High Trading VolumeKYTXKyverna Therapeutics2.8357 of 5 stars$4.03-2.2%$25.71+538.1%N/A$173.98M$7.03M0.0096Analyst ForecastAnalyst RevisionGap UpINZYInozyme Pharma1.2361 of 5 stars$2.70-3.2%$15.71+482.0%-28.5%$173.45MN/A0.0050ACTUActuate TherapeuticsN/A$8.86+3.3%N/AN/A$173.04MN/A0.0010NKTXNkarta2.2027 of 5 stars$2.44-2.4%$15.00+514.8%-4.4%$172.19MN/A-1.33140TNYATenaya Therapeutics3.9769 of 5 stars$2.14-3.6%$14.75+589.3%+18.4%$169.53MN/A0.00110Gap UpSCPHscPharmaceuticals3.8122 of 5 stars$3.34-0.6%$15.00+349.1%-40.2%$167.13M$13.59M0.0030Analyst RevisionADAPAdaptimmune Therapeutics2.1006 of 5 stars$0.65-2.8%$3.16+389.3%+54.9%$165.38M$60.28M0.00449Analyst RevisionHRTXHeron Therapeutics3.9819 of 5 stars$1.07-4.5%$5.67+429.6%-13.8%$162.75M$127.04M0.00300Analyst DowngradeShort Interest ↓ Related Companies and Tools Related Companies CRBU Competitors DMAC Competitors KYTX Competitors INZY Competitors ACTU Competitors NKTX Competitors TNYA Competitors SCPH Competitors ADAP Competitors HRTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AFMD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
